Invizyne Technologies’ (NASDAQ:IZTC – Get Free Report) lock-up period will end on Monday, May 12th. Invizyne Technologies had issued 1,875,000 shares in its IPO on November 13th. The total size of the offering was $15,000,000 based on an initial share price of $8.00. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
Invizyne Technologies Trading Down 0.4 %
Shares of NASDAQ:IZTC opened at $10.85 on Wednesday. The stock’s 50 day moving average price is $12.57. Invizyne Technologies has a twelve month low of $8.50 and a twelve month high of $23.00.
Institutional Investors Weigh In On Invizyne Technologies
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new stake in Invizyne Technologies in the 4th quarter valued at $277,000. BNP Paribas Financial Markets purchased a new position in Invizyne Technologies in the fourth quarter valued at about $35,000. Finally, Citadel Advisors LLC purchased a new position in Invizyne Technologies in the fourth quarter valued at approximately $456,000.
Invizyne Technologies Company Profile
Invizyne Technologies Inc is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc is based in Monrovia, CA.
Featured Stories
- Five stocks we like better than Invizyne Technologies
- Options Trading – Understanding Strike Price
- 3 Mid-Cap Medical Stocks Outperforming the Market
- What Makes a Stock a Good Dividend Stock?
- The Top-Ranked Insider Buys From April by Market Cap
- How to buy stock: A step-by-step guide for beginners
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for Invizyne Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invizyne Technologies and related companies with MarketBeat.com's FREE daily email newsletter.